ADGM
Adagio Medical Holdings, Inc.
Medical - Devices
Market Cap$15M
5Y Perf.-81.1%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
ADGM vs DBVT vs ALKS vs BEAT vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1690.08T
5Y Perf.+249.2%
ALKS
Alkermes plc
Biotechnology
Market Cap$5.83B
5Y Perf.+23.0%
BEAT
HeartBeam, Inc.
Medical - Healthcare Information Services
Market Cap$36M
5Y Perf.-62.1%
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.62B
5Y Perf.-59.8%
ADGM vs DBVT vs ALKS vs BEAT vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ADGM | DBVT | ALKS | BEAT | PRGO |
|---|---|---|---|---|---|
| Industry | Medical - Devices | Biotechnology | Biotechnology | Medical - Healthcare Information Services | Drug Manufacturers - Specialty & Generic |
| Market Cap | $15M | $1690.08T | $5.83B | $36M | $1.62B |
| Revenue (TTM) | $-143K | $0.00 | $1.56B | $0.00 | $4.18B |
| Net Income (TTM) | $-75M | $-168M | $153M | $-21M | $-1.82B |
| Gross Margin | -6.2% | — | 65.4% | — | 34.2% |
| Operating Margin | -232.3% | — | 12.3% | — | -4.1% |
| Forward P/E | — | — | 24.5x | — | 5.5x |
| Total Debt | $16M | $22M | $70M | $0.00 | $3.97B |
| Cash & Equiv. | $21M | $194M | $1.12B | $4M | $532M |
ADGM vs DBVT vs ALKS vs BEAT vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ADGM
DBVT
ALKS
BEAT
PRGO
| Stock | Aug 24 | May 26 | Return |
|---|---|---|---|
| Adagio Medical Hold… (ADGM) | 100 | 18.9 | -81.1% |
| DBV Technologies S.… (DBVT) | 100 | 349.2 | +249.2% |
| Alkermes plc (ALKS) | 100 | 123.0 | +23.0% |
| HeartBeam, Inc. (BEAT) | 100 | 37.9 | -62.1% |
| Perrigo Company plc (PRGO) | 100 | 40.2 | -59.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ADGM vs DBVT vs ALKS vs BEAT vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRGO leads in 3 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Alkermes plc is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. ADGM and DBVT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ADGM
Adagio Medical Holdings, Inc.
The Defensive Choice
ADGM ranks third and is worth considering specifically for stability.
- Beta 0.87 vs BEAT's 1.27
Best for: stability
DBVT
DBV Technologies S.A.
The Momentum Pick
DBVT is the clearest fit if your priority is momentum.
- +100.5% vs PRGO's -52.0%
Best for: momentum
ALKS
Alkermes plc
The Growth Play
ALKS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
- -12.0% 10Y total return vs PRGO's -77.7%
- Lower volatility, beta 1.00, Low D/E 3.8%, current ratio 3.55x
- Beta 1.00, current ratio 3.55x
Best for: growth exposure and long-term compounding
BEAT
HeartBeam, Inc.
The Healthcare Pick
Among these 5 stocks, BEAT doesn't own a clear edge in any measured category.
Best for: healthcare exposure
PRGO
Perrigo Company plc
The Income Pick
PRGO carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 10 yrs, beta 1.21, yield 9.8%
- -2.8% revenue growth vs BEAT's -100.0%
- Better valuation composite
- 9.8% yield; 10-year raise streak; the other 4 pay no meaningful dividend
Best for: income & stability
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRGO | -2.8% revenue growth vs BEAT's -100.0% |
| Value | PRGO | Better valuation composite |
| Quality / Margins | ALKS | 9.8% margin vs ADGM's -199.9% |
| Stability / Safety | ADGM | Beta 0.87 vs BEAT's 1.27 |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other 4 pay no meaningful dividend |
| Momentum (1Y) | DBVT | +100.5% vs PRGO's -52.0% |
| Efficiency (ROA) | ALKS | 5.4% ROA vs BEAT's -353.1% |
ADGM vs DBVT vs ALKS vs BEAT vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2019
FY 2025
ADGM vs DBVT vs ALKS vs BEAT vs PRGO — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLALKSLAGGINGBEAT
Who Leads Where
ALKS leads in 2 of 6 categories
PRGO leads 2 • ADGM leads 0 • DBVT leads 0 • BEAT leads 0 • 2 tied
Explore the data ↓BEATHeartBeam, Inc.
0leads
DBVTDBV Technologies S.A.
0leads
ADGMAdagio Medical Holdin…
0leads
PRGOPerrigo Company plc
2leads
ALKSAlkermes plc
2leads
6 Total Categories
CATEGORYLEADERvs PRGOvs ADGMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALKS5/6
Valuation MetricsMultiples, price ratios, and targets
PRGO4/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALKS8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
PRGO1/1
Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO and ADGM operate at a comparable scale, with $4.2B and -$143,000 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to ADGM's -199.9%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ADGMAdagio Medical Ho… | DBVTDBV Technologies … | ALKSAlkermes plc | BEATHeartBeam, Inc. | PRGOPerrigo Company p… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | -$143,000 | $0 | $1.6B | $0 | $4.2B |
| EBITDAEarnings before interest/tax | -$67M | -$112M | $212M | -$21M | $58M |
| Net IncomeAfter-tax profit | -$75M | -$168M | $153M | -$21M | -$1.8B |
| Free Cash FlowCash after capex | -$24M | -$151M | $392M | -$15M | $108M |
| Gross MarginGross profit ÷ Revenue | -6.2% | — | +65.4% | — | +34.2% |
| Operating MarginEBIT ÷ Revenue | -232.3% | — | +12.3% | — | -4.1% |
| Net MarginNet income ÷ Revenue | -199.9% | — | +9.8% | — | -43.5% |
| FCF MarginFCF ÷ Revenue | -115.6% | — | +25.1% | — | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — | +28.2% | — | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -106.3% | +91.5% | -4.1% | +22.2% | -56.4% |
ALKS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than ALKS's 17.0x.
| Metric | ADGMAdagio Medical Ho… | DBVTDBV Technologies … | ALKSAlkermes plc | BEATHeartBeam, Inc. | PRGOPerrigo Company p… |
|---|---|---|---|---|---|
| Market CapShares × price | $15M | $1690.08T | $5.8B | $36M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $11M | $1690.08T | $4.8B | $31M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.28x | -0.75x | 24.47x | -1.44x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 5.53x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 17.01x | — | 7.43x |
| Price / SalesMarket cap ÷ Revenue | 55.75x | — | 3.95x | — | 0.38x |
| Price / BookPrice ÷ Book value/share | 0.74x | 0.65x | 3.25x | 11.53x | 0.55x |
| Price / FCFMarket cap ÷ FCF | — | — | 12.14x | — | 11.17x |
PRGO leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
ALKS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-8 for ADGM. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs BEAT's 1/9, reflecting strong financial health.
| Metric | ADGMAdagio Medical Ho… | DBVTDBV Technologies … | ALKSAlkermes plc | BEATHeartBeam, Inc. | PRGOPerrigo Company p… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -7.5% | -130.2% | +8.8% | -5.7% | -50.7% |
| ROA (TTM)Return on assets | -189.8% | -89.0% | +5.4% | -3.5% | -19.8% |
| ROICReturn on invested capital | — | — | +18.9% | — | +3.7% |
| ROCEReturn on capital employed | -374.1% | -145.7% | +14.2% | -4.6% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 7 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.82x | 0.13x | 0.04x | — | 1.35x |
| Net DebtTotal debt minus cash | -$4M | -$172M | -$1.0B | -$4M | $3.4B |
| Cash & Equiv.Liquid assets | $21M | $194M | $1.1B | $4M | $532M |
| Total DebtShort + long-term debt | $16M | $22M | $70M | $0 | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | -36.69x | -189.82x | 32.30x | — | -7.20x |
ALKS leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,165 today (with dividends reinvested), compared to $1,077 for ADGM. Over the past 12 months, DBVT leads with a +100.5% total return vs PRGO's -52.0%. The 3-year compound annual growth rate (CAGR) favors DBVT at 5.7% vs ADGM's -52.4% — a key indicator of consistent wealth creation.
| Metric | ADGMAdagio Medical Ho… | DBVTDBV Technologies … | ALKSAlkermes plc | BEATHeartBeam, Inc. | PRGOPerrigo Company p… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.7% | +3.6% | +23.8% | -63.4% | -13.6% |
| 1-Year ReturnPast 12 months | -29.9% | +100.5% | +15.2% | -50.8% | -52.0% |
| 3-Year ReturnCumulative with dividends | -89.2% | +18.1% | +13.2% | -58.2% | -58.1% |
| 5-Year ReturnCumulative with dividends | -89.2% | -68.3% | +61.7% | -81.0% | -60.3% |
| 10-Year ReturnCumulative with dividends | -89.2% | -87.1% | -12.0% | -81.0% | -77.7% |
| CAGR (3Y)Annualised 3-year return | -52.4% | +5.7% | +4.2% | -25.2% | -25.2% |
Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ADGM and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADGM is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than BEAT's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 95.6% from its 52-week high vs BEAT's 22.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ADGMAdagio Medical Ho… | DBVTDBV Technologies … | ALKSAlkermes plc | BEATHeartBeam, Inc. | PRGOPerrigo Company p… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.87x | 1.26x | 1.00x | 1.27x | 1.21x |
| 52-Week HighHighest price in past year | $2.58 | $26.18 | $36.60 | $4.00 | $28.44 |
| 52-Week LowLowest price in past year | $0.74 | $7.53 | $25.17 | $0.54 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +37.8% | +75.3% | +95.6% | +22.3% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 36.5 | 47.4 | 60.5 | 39.0 | 53.1 |
| Avg Volume (50D)Average daily shares traded | 124K | 252K | 2.2M | 1.6M | 3.3M |
Evenly matched — ADGM and ALKS each lead in 1 of 2 comparable metrics.
Analyst Outlook
PRGO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ALKS as "Buy", PRGO as "Hold". Consensus price targets imply 209.1% upside for PRGO (target: $36) vs 31.5% for ALKS (target: $46). PRGO is the only dividend payer here at 9.82% yield — a key consideration for income-focused portfolios.
| Metric | ADGMAdagio Medical Ho… | DBVTDBV Technologies … | ALKSAlkermes plc | BEATHeartBeam, Inc. | PRGOPerrigo Company p… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | — | Hold |
| Price TargetConsensus 12-month target | — | $46.33 | $46.00 | — | $36.20 |
| # AnalystsCovering analysts | — | 15 | 28 | — | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — | 10 |
| Dividend / ShareAnnual DPS | — | — | — | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | 0.0% | 0.0% |
PRGO leads this category, winning 1 of 1 comparable metric.
Key Takeaway
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook). 2 tied.
Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...
ADGM vs DBVT vs ALKS vs BEAT vs PRGO: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ADGM or DBVT or ALKS or BEAT or PRGO a better buy right now?
For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.
8% revenue growth year-over-year, versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ADGM or DBVT or ALKS or BEAT or PRGO?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.
7%, compared to -89. 2% for Adagio Medical Holdings, Inc. (ADGM). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus ADGM's -89. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ADGM or DBVT or ALKS or BEAT or PRGO?
By beta (market sensitivity over 5 years), Adagio Medical Holdings, Inc.
(ADGM) is the lower-risk stock at 0. 87β versus HeartBeam, Inc. 's 1. 27β — meaning BEAT is approximately 47% more volatile than ADGM relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
04Which is growing faster — ADGM or DBVT or ALKS or BEAT or PRGO?
By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.
8% versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). On earnings-per-share growth, the picture is similar: Adagio Medical Holdings, Inc. grew EPS 27. 2% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ADGM or DBVT or ALKS or BEAT or PRGO?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -199. 9% for Adagio Medical Holdings, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -232. 3% for ADGM. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ADGM or DBVT or ALKS or BEAT or PRGO more undervalued right now?
Analyst consensus price targets imply the most upside for PRGO: 209.
1% to $36. 20.
07Which pays a better dividend — ADGM or DBVT or ALKS or BEAT or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. ADGM, DBVT, ALKS, BEAT do not pay a meaningful dividend and should not be held primarily for income.
08Is ADGM or DBVT or ALKS or BEAT or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
21), 9. 8% yield). Both have compounded well over 10 years (PRGO: -77. 7%, BEAT: -81. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ADGM and DBVT and ALKS and BEAT and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ADGM is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; BEAT is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while ADGM, DBVT, ALKS, BEAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.